Form 4: Zymeworks Executive Buys Shares via ESPP

Zymeworks' EVP, Chief Business & Financial Officer, Leone D. Patterson, acquired 459 shares of common stock through the company's Employee Stock Purchase Plan.

Summary

• Leone D. Patterson, EVP, Chief Business & Financial Officer of Zymeworks Inc. (ZYME), acquired 459 shares of common stock.
• The transaction occurred on January 6, 2026.
• Shares were purchased at a price of $10.55 per share.
• The acquisition was made pursuant to the Issuer's Amended and Restated Employee Stock Purchase Plan (ESPP).
• The purchase period for these shares was from July 1, 2025, through December 31, 2025.
• The purchase price of $10.55 represents 85% of the closing price of Zymeworks' common stock on July 1, 2025.
• Following this transaction, Leone D. Patterson beneficially owns 459 shares of common stock directly.

Sentiment

Score: 7

Explanation: The acquisition of shares by a key executive, even through a routine ESPP, generally indicates a positive sentiment and confidence in the company's future. While not a large discretionary purchase, it aligns management's interests with shareholders.

Positives

• An executive's purchase of company stock, even through an ESPP, can signal confidence in the company's future prospects.
• Participation in the ESPP demonstrates alignment of management's interests with those of shareholders.

Negatives

• No negative information is presented in this Form 4 filing.

Risks

• This Form 4 filing does not contain information regarding company-specific risks.

Future Outlook

This Form 4 filing, detailing an insider stock purchase, does not provide specific forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

Insider purchases, even through routine plans like an ESPP, are generally viewed as a positive signal within the biotechnology and pharmaceutical industry, indicating management's belief in the company's long-term value and prospects. While this specific transaction is small, it aligns with a broader trend of executives investing in their own companies.

Comparison to Industry Standards

• Employee Stock Purchase Plans (ESPPs) are a common benefit offered by publicly traded companies across various industries, including biotechnology.
• The 15% discount (85% of market price) offered by Zymeworks' ESPP is a standard and competitive discount rate compared to similar plans offered by companies like Amgen, Gilead Sciences, or Moderna, which typically range from 5% to 15%.

Stakeholder Impact

• Shareholders: The purchase by a senior executive may be interpreted as a positive signal, potentially reinforcing investor confidence in the company's outlook.
• Employees: The existence and utilization of an ESPP demonstrate a commitment to employee benefits and opportunities for wealth creation.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing.

Key Dates

Recommendation

While an insider purchase is generally a positive signal, this specific transaction is a relatively small, routine acquisition through an Employee Stock Purchase Plan (ESPP). It does not represent a significant discretionary investment that would typically warrant a change in investment recommendation. It primarily reinforces management's alignment with shareholder interests rather than indicating a major new development or undervaluation.

Keywords

Zymeworks, ZYME, Form 4, Insider Transaction, Stock Purchase, ESPP, Leone Patterson, Executive Stock Ownership